Next Article in Journal
Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort
Next Article in Special Issue
Nutritional Interventions to Improve Asthma-Related Outcomes through Immunomodulation: A Systematic Review
Previous Article in Journal
Breakfast Habits of a Representative Sample of the Spanish Child and Adolescent Population (The ENALIA Study): Association with Diet Quality
Previous Article in Special Issue
Functionally Relevant Differences in Plasma Fatty Acid Composition and Expression of Cytotoxic and Inhibitory NK Cell Receptors between Healthy Young and Healthy Elder Adults
Article

Intake of 25-Hydroxyvitamin D3 May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

FANCL Research Institute, FANCL Corporation, 12-13 Kamishinano, Totuka-ku, Yokohama 244-0806, Kanagawa, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(12), 3769; https://doi.org/10.3390/nu12123769
Received: 4 November 2020 / Revised: 27 November 2020 / Accepted: 5 December 2020 / Published: 8 December 2020
(This article belongs to the Special Issue Immune Function and Nutrient Supplementation)
To evaluate the effects of 25-hydroxyvitamin D3 (25OHD) on symptoms at the onset of the upper respiratory tract infection (URTI) in subjects with insufficient or deficient serum 25-hydroxyvitamin D levels, we conducted a post hoc analysis of data from a randomized, placebo-controlled study; the subjects received 10 μg of 25OHD per day or a placebo for 16 weeks. The Wisconsin Upper Respiratory Symptom Survey-21 was used to determine URTI. The study endpoints included WURSS-21 scores, number of URTI events, and proportion of medication (antibiotics, antipyretic analgesics) usage. We found that the physical symptom scores for “Runny nose,” “Sneezing,” and “Head congestion” were significantly lower in the 25OHD group than in the placebo group; for all items except “Breathe easily, “the quality of life” scores were significantly improved in the 25OHD group. There was no significant difference in the number of URTI events or the proportion of medication use between the groups. Collectively, the findings of this study indicate that a sufficient 25OHD intake can reduce physical symptoms at the onset of upper respiratory tract infection, particularly nasal symptoms, and may improve the quality of life at the time of onset. View Full-Text
Keywords: 25-hydroxyvitamin D3; upper respiratory tract infection; common cold 25-hydroxyvitamin D3; upper respiratory tract infection; common cold
MDPI and ACS Style

Shimizu, Y.; Ito, Y.; Uotsu, N.; Yui, K. Intake of 25-Hydroxyvitamin D3 May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study. Nutrients 2020, 12, 3769. https://doi.org/10.3390/nu12123769

AMA Style

Shimizu Y, Ito Y, Uotsu N, Yui K. Intake of 25-Hydroxyvitamin D3 May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study. Nutrients. 2020; 12(12):3769. https://doi.org/10.3390/nu12123769

Chicago/Turabian Style

Shimizu, Yoshiki, Yukihiko Ito, Nobuo Uotsu, and Kei Yui. 2020. "Intake of 25-Hydroxyvitamin D3 May Reduce the Severity of Upper Respiratory Tract Infection: Post hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study" Nutrients 12, no. 12: 3769. https://doi.org/10.3390/nu12123769

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop